Newswire (Published: Monday, October 30, 2017, Received: Thursday, October 26, 2017, 3:47:26 PM CDT)

Word Count: 476

Study Results from Kanazawa University Provide New Insights into Prostate Cancer [Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a ...]

By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting from Ishikawa, Japan, by NewsRx journalists, research stated, "Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. These oral agents target androgen and androgen receptor signaling and are thought to be less toxic than chemotherapy."

The news correspondents obtained a quote from the research from Kanazawa University, "Cross-resistance to these agents was recently reported because of their similar mechanism of action, and it is important to assess which agent is more effective to use initially for CRPC. The present study is a phase III, investigator-initiated, multicenter, head-to-head, randomized controlled trial investigating enzalutamide vs. abiraterone as a first-line treatment for CRPC patients. Patients will be randomly assigned to an enzalutamide or an abiraterone treatment group. The primary endpoint is the time to prostate-specific antigen progression. The target sample size is set at 100 patients per group (total, 200 patients). The study duration is 5 years, and the duration for recruitment is 2 years and 6 months. Thus far, there have been no prospective head-to-head studies comparing enzalutamide and abiraterone."

According to the news reporters, the research concluded: "This ENABLE study will clarify which agent should be prioritized for CRPC patients and enable clinicians to decide the appropriate treatment before chemotherapy."

For more information on this research see: Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC Cancer, 2017;17():14-19. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)

Our news journalists report that additional information may be obtained by contacting K. Izumi, Kanazawa University, Dept. of Integrat Canc Therapy & Urol, Grad Sch Med Sci, Kanazawa, Ishikawa 9208641, Japan. Additional authors for this research include A. Mizokami, M. Namiki, S. Inoue, N. Tanaka, Y. Yoshio, K. Ishibashi, M. Kamiyama, N. Kawai, H. Enokida, T. Shima and S. Takahara (see also Oncology - Prostate Cancer).

Keywords for this news article include: Ishikawa, Japan, Asia, Clinical Trials and Studies, Prostatic Neoplasms, Endocrine Research, Clinical Research, Prostate Cancer, Oncology, Therapy, Kanazawa University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Kanazawa University
Biomed Central Limited

Places

Eastern Asia
Northern Europe
United Kingdom
Japan
Asia
Europe
England
London

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Endocrine Disorders
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
            Pharmaceutical Development
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process